Issue Highlights

2023;112 (1): 93 - 99. 5 Himmelmann K, Påhlman M. The panorama of cerebral palsy in Sweden part XIII shows declining prevalence in birth-years 2011-2014. The latest phase of this lengthy, ongoing study showed a significant decrease in the prevalence of cerebral palsy in children born from 2011 to 2014.[5] The decline was mainly seen in term-born children, while the prevalence in children born extremely preterm was unchanged. Sweden initially chose a different disease prevention and control path to many other countries during the COVID-19 pandemic. [Extracted from the article]

Management of Children with Severe COVID-19 in a Pediatrics Unit in Istanbul: A Retrospective Study

Objective: SARS-CoV-2 is a probable causative agent of severe disease both in children and adults. In this study, we aimed to evaluate the management of hospitalized severe pediatric COVID-19 patients. Methods: Data on the management of 21 children under the age of 18 who were hospitalized with severe COVID-19 between March 2020 and May 2020 were included in this study. Results: A total of 1109 patients, including 888 outpatients and 221 inpatients, were included in this study. 91 (41.1%) of the 221 hospitalized children were PCR positive for SARS-CoV-2. 21 (23%) of 91 COVID-19 patients were considered severe COVID-19. 10 (47.6%) were females and 11 (52.4%) were males, with a mean±standard deviation (SD) age of 14.4±2.7 years (range;9 years-17.6 years). The most prevalent symptoms at admission were fever (80.9%), cough (76.1%), shortness of breath (23.8%) and myalgia (23.8%). 4 (19%) of 21 patients had underlying diseases. 19 (90.4%) patients were in close contact with confirmed cases in the family. All patients had typical findings on lung computed tomography (CT) and the major CT abnormalities observed were ground-glass opacities. Two patients who needed respiratory support received favipiravir treatment. The mean hospital stay was 7.34±2.65 (5-16) days. Clinical improvement was achieved in all patients. Conclusion: The clinical course of COVID-19 in children is milder and has a better prognosis than adults, but it should be kept in mind that severe cases are defined in the pediatric patient group and these patients should be followed closely. (English) [ FROM AUTHOR] Amaç: SARS-CoV-2, hem çocuklarda hem de yetişkinlerde ciddi hastalığın olası bir etkenidir. Bu çalışmada, hastanede yatan ağır çocuk COVID-19 hastalarının yönetimini değerlendirmeyi amaçladık. Gereç ve Yöntem: Mart 2020 ile Mayıs 2020 tarihleri arasında 18 yaş altı ağır COVID-19'lu hastanede yatan 21 çocuğun yönetimine ilişkin veriler bu çalışmaya dahil edildi. Bulgular: Bu çalışmada 888 ayaktan ve 221 yatan hasta olmak üzere toplam 1109 hasta toplandı. Hastanede yatan 221 çocuğun 91'i (%41.1) SARS-CoV-2 için PCR pozitifti. Doksan bir COVID-19 hastasının 21'i (%23) şiddetli COVID-19 olarak kabul edildi. Onu (%47.6) kız, 11'i (%52.4) erkek olup, yaşları ortalama±standart sapma (SS) 14.4±2.7 yıl (aralık;9 yıl-17.6 yıl) olarak saptandı. En sık başvuru semptomları ateş (%80.9), öksürük (%76.1), nefes darlığı (%23.8) ve miyalji (%23.8) idi. Yirmi bir hastanın dördünde (%19) altta yatan hastalık vardı. On dokuz (%90.4) hasta ailede doğrulanmış olgularla yakın temas halindeydi. Tüm hastalarda tipik olarak akciğer bilgisayarlı tomografi (BT) bulguları vardı ve başlıca gözlenen BT anormallikleri buzlu cam opasiteleriydi. Solunum desteğine ihtiyaç duyan iki hasta favipiravir tedavisi aldı. Ortalama hastanede kalış süresi 7.34±2.65 (5-16) gündü. Tüm hastalarda klinik iyileşme sağlandı. Sonuç: Çocuklarda COVID-19'un yetişkinlere göre klinik seyri daha hafiftir ve daha iyi prognozu vardır ancak çocuk hasta grubunda ciddi olgular tanımlandığı ve bu hastaların yakından takip edilmesi gerektiği akılda tutulmalıdır. (Turkish) [ FROM AUTHOR] Copyright of Southern Clinics of Istanbul Eurasia is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

A CASE OF ADULT MULTISYSTEM INFLAMMATION SYNDROME FOLLOWING COVID-19 VACCINE

It is unclear that this post vaccination MIS is the same as post SARS-COV-2 MIS-A and MIS-C. Future research into the potential pathophysiological mechanisms are important as the vaccine is now universally recommended. After ruling out all potential differential diagnosis including infectious, vasculitis, thrombotic, and immune etiology, a diagnosis of MIS secondary to mRNA Covid-19 vaccination was made and reported to the CDC. B Introduction: b Multisystem inflammation syndrome (MIS) is a condition characterized by fever, multi organ dysfunction, elevated inflammatory markers and temporally associated with COVID-19 infection. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)